The global Frontotemporal Disorders Treatment Market value at around USD 343.8 million in 2022, registering Y-o-Y growth of 4.4%. The market is projected to increase at a CAGR of 4.6% and reach a valuation of USD 451.4 million by 2028.
| Attribute | Details |
|---|---|
| Frontotemporal Disorders Treatment Market Size (2022) | USD 343.8 million |
| Sales Forecast (2028) | USD 451.4 million |
| Global Market Growth Rate (2022 to 2028) | 4.6% CAGR |
| Share of Top 5 Frontotemporal Disorders Treatment System Providers | 50% |
Currently, frontotemporal disorders treatment holds a share of 4.4% of the global neurological disorder treatment market.
| Particulars | Details |
|---|---|
| H1, 2021 | 4.69% |
| H1, 2022 Projected | 4.64% |
| H1, 2022 Outlook | 4.44% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 20 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 25 ↓ |
As per the FMI analysis, H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 20 BPS. However, In H1-2022, the market growth rate of frontotemporal disorders treatment is expected to fall by 25 basis point share (BPS).
The decline in the BPS values observed was attributed the fact that there exist no current disease-modifying drugs approved by the regulatory bodies for the treatment of frontotemporal disorders. With growing changes in lifestyle, and the growing global burden of disease in ageing population, the market faced a heavy demand over the last few decades. With a large gap in the demand and supply, the market likely observed this decline in the BPS values.
Conversely, with advancements in behavioural therapy approaches, the management of symptomatic concerns regarding frontotemporal disorders will provide insights into the growth of the overall market during the forecast years.
The market is highly influenced by patient pool, treatment adoption rate, target population group demography, and disease prevalence, under the impact of macro and industry factors.
Growing Prevalence of Dementia Expected to Propel Demand for Frontotemporal Disorders Treatment Drugs
During the historical period of 2013 to 2021, the frontotemporal disorders treatment market expanded at a CAGR of 4.4%.
Frontotemporal disorders are a bunch of rare disorders that include shrinkage of a particular portion of the brain that controls personality, language, and behavior. The condition arises due to the degeneration of frontotemporal cells, which is called frontotemporal lobar degeneration (FTLD).
The typical age range for the onset of frontotemporal dementia is 40 to 60 years; however, it can start after 60 years of age, and the maximum life expectancy after diagnosis is 8–10 years.
With severe dearth of frontotemporal disorders treatment drugs for the reliable treatment of frontotemporal disorders, treatment continues to underscore the growing significance of disease management. As frontotemporal disorders treatment exclusively includes symptomatic efforts to date, the condition continues to attract research interests worldwide.
Available frontotemporal disorders treatment drugs and other means of frontotemporal disorders treatment do not stop or even decelerate frontotemporal disorders progression, which further remains a key driving force for growing demand for frontotemporal disorders treatment. Expanding incentives for orphan drug development is identified as a prominent factor pushing revenue growth of the frontotemporal disorders treatment industry.
Considering the aforementioned factors, the global frontotemporal disorders treatment market is anticipated to rise at 4.6% CAGR across the 2022 to 2028 time frame.
Increasing FTD Drug Development Grants & Funding by Non-Profit Organizations Driving Market Growth
Non-profit organizations and disease advocacy & private organizations currently are focusing on supporting FTD drug development as the patient base of FTD is expanding. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal disorders treatment drugs.
These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop FTD and other rare neurological disease progressions.
Rising life expectancy rate is another major factor expected to boost the growth of the frontotemporal disorders treatment market due to the high prevalence of neurological disease among the older population. Population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia.
Misdiagnosis and Lack of Awareness Limiting Adoption of Neurological Conditions Treatment
Frontotemporal disorders are often misdiagnosed as depression, Parkinson’s, Alzheimer’s, or other psychiatric conditions, thereby limiting the scope of adoption of neurological conditions treatment.
Though clinical trials have resulted in many interventions other than medication, consistently high rate of clinical trial failures is a significant factor that is influencing the growth prospects of neurological conditions treatment.
Ongoing Clinical Trials for Frontotemporal Lobar Degeneration (FTLD) to Boost Market Expansion in Western Europe
Western Europe is expected to contribute 30.5% share in the global frontotemporal disorders treatment market in 2022.
While rapidly growing FTD prevalence and expanding ongoing clinical trials platforms are providing a collective push to the frontotemporal disorders treatment market in Western Europe, research estimates rapid emergence owing to increasing sophistication of the healthcare sector and gradually surging awareness about frontotemporal lobar degeneration (FTLD).
Orphan Drug Development Incentives by FDA to Push the Market Forward
Frontotemporal dementia falls under rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the USA Treatment of FTD falls under auspices of the Orphan Drug Act of 1983 as orphan drug indications are those that affect less than 200,000 people in the USA .
Orphan drug designation to FTD allows the continuation of clinical trial and orphan drug development with commercial incentives, prioritized consultation by FDA on clinical studies, and reduction in regulatory fees.
Presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool is expected to fuel market growth in the USA .
Higher Prevalence of Frontotemporal Disorders in Older Age Group to Fuel Market Expansion
China, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment systems market.
The market in China is predicted to develop at the quickest rate due to increased disposable income. Moreover, the market growth is related to increasing prevalence of frontotemporal disorders due to the growing elderly population base, as well as the poor immune system.
Initiatives by Mental Treatment Centers for Frontotemporal Dementia Patients to Boost Market Growth
Based on disease indication, frontotemporal dementia (FTD), holding a massive market value share, remains the most common indication among all that continues to capture clinical research interests.
Rapid development of new frontotemporal dementia therapies will push collaborative activities among clinical research entities, educational institutions, academic laboratories, pharma and biotech centers, and the FDA.
Furthermore, frontotemporal dementia therapeutics are anticipated to witness major contributions from pharmaceutical companies – eventually boosting the funding and clinical trial scenario.
Hospital Pharmacies Most Preferred Due to Easy Availability of Frontotemporal Disorders Treatment Drugs
Hospital pharmacies are expected to hold the highest market share over the forecast period. Majority of frontotemporal problems are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
However, there are no specific treatments available to entirely stop the course of frontotemporal disorders. As a result, doctors may prescribe antidepressant medicines to help with anxiety and other symptoms.
In a highly fragmented landscape of the global frontotemporal disorders treatment market, almost 70% of companies offer generics as their key drug offerings. Operated by a large number of prominent international, multinational, and regional players, the market for frontotemporal disorders treatment is recently witnessing a heap of strategic deals, including acquisitions, collaborations, and alliances.
For instance,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | Value in USD million |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | USA, Canada, Mexico, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Nordic, Spain, Japan, China, India, Malaysia, Thailand, Australia, GCC Countries, South Africa, Turkey |
| Key Market Segments Covered |
Drug Class, Treatment, Disease Indication, Distribution Channel, Region |
| Key Companies Profiled | Pfizer Inc.; Johnson & Johnson; Sanofi S.A.; Eli Lilly and Company; GlaxoSmithKline Plc.; Novartis AG; Mylan N.V.; Merck & Company, Inc.; AstraZeneca plc.; Allergen plc |
| Pricing | Available upon Request |
Table 01: NIH Estimated Funding for Frontotemporal Dementia
Table 02: Frontotemporal Disorders Treatment Market Opportunity Pipeline Analysis (2021)
Table 03: Frontotemporal Disorders Treatment Market Opportunity Pipeline Analysis (2021)
Table 04: Non-Profit Organizations Driving FTD Therapeutics Development
Table 05: Non-Profit Organizations Driving FTD Therapeutics Development
Table 06: World Population Aged 65 and Over by Sex: 2015, 2030, and 2050 (Numbers in millions)
Table 07: Prevalence of Frontotemporal Dementia, By Region
Table 08: Prevalence of Frontotemporal Dementia, By Region
Table 09: Prevalence of Primary Progressive Aphasia , By Region
Table 10: Prevalence of Primary Progressive Aphasia , By Region
Table 11: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 12: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 13: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 14: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 15: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 16: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 17: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 18: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 19: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 20: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 21: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 22: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 23: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 24: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 25: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 26: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 27: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 28: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 29: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 30: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 31: APEJ Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 32: APEJ Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 33: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 34: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 35: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 36: Japan Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 37: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 38: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 39: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 40: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 41: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 42: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 43: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 44: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 45: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Region
Table 46: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 47: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Treatment Type
Table 48: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 49: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Figure 1: Global Frontotemporal Disorders Treatment Market Split By Drug Class (2022)
Figure 2: Global Frontotemporal Disorders Treatment Market Split Treatment Type (2022)
Figure 3: Global Frontotemporal Disorders Treatment Market Split By Distribution Channel (2022)
Figure 4: Global Frontotemporal Disorders Treatment Market Split By Disease Indication (2022)
Figure 5: Global Frontotemporal Disorders Treatment Market Split By Region (2022)
Figure 6: Economic Burden of Major Neurological Disease in United States % (2014)
Figure 7: Distribution of Industry Sponsored Clinical Programs for Frontotemporal Disorders Drugs, by Phase
Figure 8: Global Impact of Dementia
Figure 9: Incidence of FTD By Age
Figure 10: Prevalence of Frontotemporal Dementia Across the Globe
Figure 11: Prevalence of Primary Progressive Aphasia (PPA) Across the Globe
Figure 12: North America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 13: North America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 14: U.S. Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 15: U.S. Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 16: Canada Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 17: Canada Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 18: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 19: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 20: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 21: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 22: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 23: Latin America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 24: Latin America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 25: Brazil Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 26: Brazil Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 27: Mexico Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 28: Mexico Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 29: Rest of Latin America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 30: Rest of Latin America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 31: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 32: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 33: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 34: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 35: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 36: Western Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 37: Western Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 38: Germany Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 39: Germany Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 40: Italy Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 41: Italy Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 42: France Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 43: France Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 44: U.K. Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 45: U.K. Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 46: Spain Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 47: Spain Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 48: Rest of Western Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 49: Rest of Western Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 50: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 51: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 52: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 53: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 54: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 55: Eastern Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 56: Eastern Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 57: Russia Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 58: Russia Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 59: Poland Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 60: Poland Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 61: Rest of Eastern Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 62: Rest of Eastern Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 63: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 64: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 65: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 66: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 67: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 68: APEJ Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 69: APEJ Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 70: China Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 71: China Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 72: India Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 73: India Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 74: Australia Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 75: Australia Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 76: ASEAN Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 77: ASEAN Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 78: Rest of APEJ Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 79: Rest of APEJ Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 80: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 81: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 82: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 83: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 84: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 85: Japan Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 86: Japan Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 87: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 88: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 89: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 90: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 91: MEA Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 92: MEA Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 93: GCC Countries Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 94: GCC Countries Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 95: South Africa Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 96: South Afric Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 97: Rest of MEA Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 98: Rest of MEA Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 99: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 100: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 101: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 102: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 103: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 104: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Region
Figure 105: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 106: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 107: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 108: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 109: Global Frontotemporal Disorders Treatment Market Historical Market Value and Y-o-Y, 2013-2022
Figure 110: Global Frontotemporal Disorders Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 111: Global Frontotemporal Disorders Treatment Market Absolute $ Opportunity, 2013–2028
As of 2022, the global frontotemporal disorders treatment market is expected to reach USD 343.8 Milllion.
France, China, Germany, India, and the USA are the top 5 countries driving most demand for frontotemporal disorders treatment.
Pfizer Inc., Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, and GlaxoSmithKline Plc. are leading companies in this market.
The frontotemporal disorders treatment market is expected to rise at a CAGR of around 4.6% during the period of 2022 to 2028.
Western Europe accounts for 30.5% share of the global frontotemporal disorders treatment market.
Explore Similar Insights
Frontotemporal Disorders Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
